(19)
(11) EP 3 319 980 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.11.2021 Bulletin 2021/44

(45) Mention of the grant of the patent:
29.09.2021 Bulletin 2021/39

(21) Application number: 16824940.7

(22) Date of filing: 08.07.2016
(51) International Patent Classification (IPC): 
C07K 14/00(2006.01)
A61K 9/127(2006.01)
 A61K 9/107(2006.01)
C12Q 1/48(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/00; A61P 35/00; A61K 38/16; A61K 9/127
(86) International application number:
PCT/US2016/041544
(87) International publication number:
WO 2017/011312 (19.01.2017 Gazette 2017/03)

(54)

FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS

FORMULIERUNGEN ZUR VERBESSERUNG DER WIRKSAMKEIT VON HYDROPHOBEN ARZNEIMITTELN

FORMULATIONS PERMETTANT D'AMÉLIORER L'EFFICACITÉ DES MÉDICAMENTS HYDROPHOBES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 10.07.2015 US 201562190909 P

(43) Date of publication of application:
16.05.2018 Bulletin 2018/20

(73) Proprietor: Peptinovo Biopharma Inc.
Ann Arbor, MI 48103 (US)

(72) Inventors:
  • HOMAN, Reynold
    Ann Arbor, MI 48108 (US)
  • ELLIOTT, William, L.
    Ann Arbor, MI 48103 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
WO-A2-2009/155366
US-A1- 2014 024 061
 US-A1- 2009 110 739
   
  • ZHIHONG ZHANG ET AL: "Biomimetic Nanocarrier for Direct Cytosolic Drug Delivery", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 48, no. 48, 16 November 2009 (2009-11-16), pages 9171-9175, XP055538201, DE ISSN: 1433-7851, DOI: 10.1002/anie.200903112
  • ZHIHONG ZHANG ET AL: "HDL-Mimicking Peptide-Lipid Nanoparticles with Improved Tumor Targeting", SMALL, vol. 6, no. 3, 5 February 2010 (2010-02-05), pages 430-437, XP055247522, DE ISSN: 1613-6810, DOI: 10.1002/smll.200901515
  • JULIEN BALZEAU ET AL: "The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells", BIOMATERIALS, vol. 34, no. 13, 1 April 2013 (2013-04-01) , pages 3381-3389, XP055141672, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2013.01.068
  • DATTA G ET AL: "Effects of increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide", JOURNAL OF LIPID RESEARCH, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 42, 1 January 2001 (2001-01-01), pages 1096-1104, XP003013496, ISSN: 0022-2275
  • DONG ET AL.: 'Long-circulating 15 nm micelles based on amphiphilic 3-helix peptide-PEG conjugates.' ACS NANO vol. 6, no. 6, 26 June 2012, pages 5320 - 5329, XP055046013
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).